US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

Pre-open movers US stock futures gained in early pre-market trade, ahead of earnings from several major companies. The Federal Open Market Committee will begin its two-day policy meeting today. The S&P/Case-Shiller home price index for February will be released at 9:00 a.m. ET, while the Conference Board's consumer confidence index for April will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average surged 42 points to 16,439.00, while the Standard & Poor's 500 index futures rose 5.70 points to 1,871.70. Futures for the Nasdaq 100 index gained 16.25 points to 3,557.00. A Peek Into Global Markets European markets were higher today, with the Spanish Ibex Index rising 0.84%, London's FTSE 100 index gaining 0.66% and STOXX Europe 600 Index surging 0.74%. German DAX 30 index gained 1.19% and French CAC 40 Index rose 0.42%. UK's economy expanded 0.8% in the first quarter. Spain's unemployment rate increased to 25.9% in the first quarter. French consumer confidence fell to 85 in April versus 88 in March. Asian markets ended mostly higher today. Hong Kong's Hang Seng Index surged 1.45%, China's Shanghai Composite rose 0.84% and India's BSE Index declined 0.73%. Broker Recommendation Analysts at Bank of America upgraded Chegg CHGG from “neutral” to “buy.” The target price for Chegg is set to $8. Chegg's shares closed at $5.25 yesterday. Breaking news
  • Teva Pharmaceutical TEVA announced today that the European Commission has granted marketing authorization for DuoResp Spiromax® for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate. To read the full news, click here.
  • BP plc BP posted a drop in its first-quarter profit and raised its dividend. To read the full news, click here.
  • Bristol-Myers Squibb Company BMY and iPierian announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain. To read the full news, click here.
  • Archer Daniels Midland Co ADM reported weaker-than-expected first-quarter earnings. ADM's quarterly profit slipped to $267 million, or $0.40 per share, versus a year-ago profit of $269 million, or $0.41 per share. To read the full news, click here.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsBank of AmericaUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!